Hadfield K D, Newman W G, Bowers N L, Wallace A, Bolger C, Colley A, McCann E, Trump D, Prescott T, Evans D G R
Academic Unit of Medical Genetics, University of Manchester and Regional Genetics Service, Manchester, UK.
J Med Genet. 2008 Jun;45(6):332-9. doi: 10.1136/jmg.2007.056499. Epub 2008 Feb 19.
Schwannomatosis is a rare condition characterised by multiple schwannomas and lack of involvement of the vestibular nerve. A recent report identified bi-allelic mutations in the SMARCB1/INI1 gene in a single family with schwannomatosis. We aimed to establish the contribution of the SMARCB1 and the NF2 genes to sporadic and familial schwannomatosis in our cohort.
We performed DNA sequence and dosage analysis of SMARCB1 and NF2 in 28 sporadic cases and 15 families with schwannomatosis.
We identified germline mutations in SMARCB1 in 5 of 15 (33.3%) families with schwannomatosis and 2 of 28 (7.1%) individuals with sporadic schwannomatosis. In all individuals with a germline mutation in SMARCB1 in whom tumour tissue was available, we detected a second hit with loss of SMARCB1. In addition, in all affected individuals with SMARCB1 mutations and available tumour tissue, we detected bi-allelic somatic inactivation of the NF2 gene. SMARCB1 mutations were associated with a higher number of spinal tumours in patients with a positive family history (p = 0.004).
In contrast to the recent report where no NF2 mutations were identified in a schwannomatosis family with SMARCB1 mutations, in our cohort, a four hit model with mutations in both SMARCB1 and NF2 define a subset of patients with schwannomatosis.
神经鞘瘤病是一种罕见疾病,其特征为多发性神经鞘瘤且前庭神经未受累。最近一份报告在一个患有神经鞘瘤病的家族中发现了SMARCB1/INI1基因的双等位基因突变。我们旨在确定SMARCB1和NF2基因对我们队列中散发性和家族性神经鞘瘤病的影响。
我们对28例散发性病例和15个患有神经鞘瘤病的家族进行了SMARCB1和NF2的DNA序列及剂量分析。
我们在15个(33.3%)患有神经鞘瘤病的家族中的5个以及28个(7.1%)散发性神经鞘瘤病个体中的2个中鉴定出了SMARCB1的种系突变。在所有可获取肿瘤组织且存在SMARCB1种系突变的个体中,我们检测到了SMARCB1缺失的第二次打击。此外,在所有携带SMARCB1突变且可获取肿瘤组织的受累个体中,我们检测到了NF2基因的双等位基因体细胞失活。SMARCB1突变与有家族史患者中更多的脊柱肿瘤相关(p = 0.004)。
与最近一份在一个携带SMARCB1突变的神经鞘瘤病家族中未鉴定出NF2突变的报告不同,在我们的队列中,一种涉及SMARCB1和NF2均突变的四重打击模型定义了一部分神经鞘瘤病患者。